VRNA Relative Valuation
VRNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VRNA is overvalued; if below, it's undervalued.
Historical Valuation
Verona Pharma PLC (VRNA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 18.27 is considered Undervalued compared with the five-year average of -68.61. The fair price of Verona Pharma PLC (VRNA) is between 126.59 to 277.29 according to relative valuation methord. Compared to the current price of 104.81 USD , Verona Pharma PLC is Undervalued By 17.2%.
Relative Value
Fair Zone
126.59-277.29
Current Price：104.81
17.2%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
39.36
P/B
Median3y
11.53
Median5y
7.81
-1.36
FCF Yield
Median3y
-3.49
Median5y
-6.11
Competitors Valuation Multiple
The average P/S ratio for VRNA's competitors is 52.60, providing a benchmark for relative valuation. Verona Pharma PLC Corp (VRNA) exhibits a P/S ratio of 18.34, which is -65.13% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Verona Pharma PLC (VRNA) currently overvalued or undervalued?
What is Verona Pharma PLC (VRNA) fair value?
How does VRNA's valuation metrics compare to the industry average?
What is the current P/B ratio for Verona Pharma PLC (VRNA) as of Jul 17 2025?
What is the current FCF Yield for Verona Pharma PLC (VRNA) as of Jul 17 2025?
What is the current Forward P/E ratio for Verona Pharma PLC (VRNA) as of Jul 17 2025?